BioCentury | Feb 28, 2020
Distillery Therapeutics

A PON-1 gene therapy to protect against nerve agent poisoning

...DISEASE CATEGORY: Other INDICATION: Poisoning A gene therapy delivering a variant of a PON-1, a hydrolytic...
...agents. The gene therapy comprises a liver-targeted adeno-associated virus serotype 8 (AAV8) vector encoding the PON-1...
...100% for all other challenges. Next steps include testing in large animal models. TARGET/MARKER/PATHWAY: Paraoxonase-1 (PON-1...
BioCentury | May 16, 2018
Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected...
BioCentury | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
BioCentury | Jul 25, 2016
Emerging Company Profile

Targeted phagocytosis

Alexo Therapeutics Inc. is developing variants of signal regulatory protein alpha that antagonize CD47 to increase macrophage phagocytosis induced by anticancer antibodies. Using the variants alongside antibody therapeutics could avoid on-target phagocytosis of healthy cells...
BioCentury | May 9, 2016
Finance

ven and now

Strategic LPs once again dominate the second fund from venBio LLC, even though none of the first fund's M&A exits went to an LP. The firm's Global Strategic Fund II closed last week at $315...
BioCentury | May 6, 2016
Top Story

venBio closes $315M fund

venBio closed its Global Strategic Fund II with $315 million, above its initial target of $250 million. Strategic LPs Amgen Inc. (NASDAQ:AMGN), Merck & Co. Inc. (NYSE:MRK) and Baxalta Inc. (NYSE:BXLT) contributed most of the...
BioCentury | Jan 27, 2011
Distillery Techniques

Technology: Markers

...contact information Markers Paraoxonase-1 (^PON-1) genotyping to guide use of clopidogrel to prevent stent thrombosis PON-1...
...to inefficient metabolism and activation of the drug. In vitro metabolomic profiling showed that the PON-1...
...receiving clopidogrel, homozygous subjects were more likely to have lower plasma amounts of both active PON-1...
BioCentury | Jan 27, 2011
Tools & Techniques

Once a PON-1 an enzyme

...Now, a European team has put a new enzyme on the map- ^ paraoxonase-1 ( PON-1...
...that PON-1 played a critical role in activating Plavix ( see "Activation of clopidogrel" ). PON-1...
...the association of platelet inhibition with the PON-1 locus." Decisions, decisions If the findings about PON-1...
BioCentury | Nov 13, 2008
Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Fusion protein for drug delivery across the blood-brain barrier (BBB) An in vitro study suggests that linking paraoxonase 1 (PON1) to...
BioCentury | Nov 13, 2008
Tools & Techniques

ArmaGen's gatecrashers

Over the past few years, ArmaGen Technologies Inc. and collaborators at the University of California, Los Angeles , have published a series of studies describing genetically engineered fusion proteins to shuttle therapeutics across the blood-brain barrier....
Items per page:
1 - 10 of 18